Skip to main content

Table 2 Tumour-associated antigens and corresponding CAR-Ts, ADCs or BiTEs

From: Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Tumour-associated antigens (targets) Biological function Agent Study phase Research tumour type Reference
Tn-MUC1
Sialyl-Tn-MUC1
Alter cancer cell adhesion and motility 5E5 CAR T Mouse Model Leukemia, PDAC, Breast cancer 2016, Immunity
B7-H3 T cell co-stimulatory molecule B7-H3. CAR T Patient derived xenograft PDAC, Ovarian cancer, Neuroblastoma 2019, Cancer Cell
Mesothelin Tumour local invasion and metastasis MSLN CARs Phase I Mesothelioma,
Ovarian carcinoma,
PDAC
NCT02159716
Anetumab ravtansine Phase I Mesothelioma,
Ovarian carcinoma,
PDAC, etc
NCT03102320
CEA Tumour surface biomarker CEA-CAR-T Mouse models Colorectal cancer, Gastric cancer, PDAC 2019, Cancer Medicine
Phase II/III PDAC NCT04037241
Mesothelin & CEA   dCAR-T Cell models PDAC 2018, Journal of Hematology and Oncology
KRAS G12D
HLA-C*08:02
Tumour formation and progression CTL targeting KRAS G12D Phase II Metastatic cancers (Colorectal cancer, Glioblastoma, PDAC, Ovarian cancer, Breast cancer) 2016, New England Journal of Medicine
NCT01174121
HER2/ERBB2 Tumorigenesis and tumour proliferation Switchable CAR T against HER2 Xenograft model PDAC 2019, Gut
CART-HER2 Phase I Biliary tract cancer, PDAC NCT01935843
DS-8201a Phase I Solid tumors 2016, Clinical Cancer Research
CD133 Tumour stem cells marker CAR T-133 Phase I Hepatocellular carcinoma, Colorectal carcinoma, PDAC NCT02541370
PD-1 Immune checkpoint chPD1 T cells Mouse model Solid tumors (melanoma, renal cancer, liver cancer, PDAC, etc.) 2020, Immunology
MUC16 Tumour surface biomarker DMUC5754A Phase I Ovarian cancer, PDAC NCT01335958
Guanylyl cyclase C Membrane receptor MLN0624 Phase II PDAC NCT02202785
Glypican-1 Cell surface proteoglycan GPC-1-ADC Patient derived xenograft PDAC 2020, British Journal of Cancer
EpCAM Cell adhesion MT110 Phase I Colorectal cancer, Ovarian cancer, Gastric cancer, Lung cancer, Prostate cancer NCT00635596
  1. PDAC pancreatic ductal adenocarcinoma; CAR-T chimeric antigen receptor T cells; ADC antibody-drug conjugate; BiTE bispecific T-cell engager; MSLN Mesothelin; CTL cytotoxic T lymphocytes; PD-1 programmed death-1 receptor